ES2690971T3 - Compuestos pirimido-piridazinona y uso de los mismos - Google Patents

Compuestos pirimido-piridazinona y uso de los mismos Download PDF

Info

Publication number
ES2690971T3
ES2690971T3 ES12756865T ES12756865T ES2690971T3 ES 2690971 T3 ES2690971 T3 ES 2690971T3 ES 12756865 T ES12756865 T ES 12756865T ES 12756865 T ES12756865 T ES 12756865T ES 2690971 T3 ES2690971 T3 ES 2690971T3
Authority
ES
Spain
Prior art keywords
alkyl
substituted
alkoxy
hydroxyalkyl
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12756865T
Other languages
English (en)
Spanish (es)
Inventor
Aranapakam Venkatesan
Roger Astbury Smith
Subramanya Hosahalli
Vijay Potluri
Sunil Kumar Panigrahi
Vishnu BASETTI
Karunasree KUNTU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asana Biosciences LLC
Original Assignee
Asana Biosciences LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asana Biosciences LLC filed Critical Asana Biosciences LLC
Application granted granted Critical
Publication of ES2690971T3 publication Critical patent/ES2690971T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ES12756865T 2011-08-23 2012-08-23 Compuestos pirimido-piridazinona y uso de los mismos Active ES2690971T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161526525P 2011-08-23 2011-08-23
PCT/US2012/051980 WO2013028818A1 (en) 2011-08-23 2012-08-23 Pyrimido- pyridazinone compounds and use thereof

Publications (1)

Publication Number Publication Date
ES2690971T3 true ES2690971T3 (es) 2018-11-23

Family

ID=46829884

Family Applications (2)

Application Number Title Priority Date Filing Date
ES12756865T Active ES2690971T3 (es) 2011-08-23 2012-08-23 Compuestos pirimido-piridazinona y uso de los mismos
ES18175788T Active ES2969977T3 (es) 2011-08-23 2012-08-23 Compuestos de pirimido-piridazinona y uso de los mismos

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES18175788T Active ES2969977T3 (es) 2011-08-23 2012-08-23 Compuestos de pirimido-piridazinona y uso de los mismos

Country Status (14)

Country Link
US (5) US8729079B2 (enExample)
EP (4) EP4327886A3 (enExample)
JP (1) JP5993010B2 (enExample)
CN (2) CN108707151B (enExample)
BR (1) BR112014003981A2 (enExample)
CA (1) CA2846187A1 (enExample)
DK (2) DK2748166T3 (enExample)
ES (2) ES2690971T3 (enExample)
FI (1) FI3392252T3 (enExample)
HU (1) HUE065564T2 (enExample)
IL (1) IL231082A (enExample)
MX (1) MX361458B (enExample)
PL (1) PL2748166T3 (enExample)
WO (1) WO2013028818A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX361458B (es) * 2011-08-23 2018-12-06 Asana Biosciences Llc Compuestos de pirimido-piridazinona y uso de los mismos.
AR106830A1 (es) * 2015-12-04 2018-02-21 Asana Biosciences Llc Usos de piridazinonas para tratar el cáncer
WO2018187294A1 (en) * 2017-04-03 2018-10-11 Asana Biosciences, Llc Pyrimido-pyridazinone compound combinations, methods, kits and formulations thereof
WO2018201131A1 (en) 2017-04-28 2018-11-01 Asana Biosciences, Llc Formulations, methods, kits, and dosage forms for treating atopic dermatitis and for improved stability of an active pharmaceutical ingredient
CN111961035B (zh) * 2019-05-20 2022-11-01 南京科技职业学院 一类含有羟基异喹啉类结构的化合物、药物组合物以及其应用
WO2021027943A1 (zh) * 2019-08-14 2021-02-18 正大天晴药业集团南京顺欣制药有限公司 哒嗪酮并嘧啶类衍生物及其医药用途
CN113583026B (zh) * 2020-04-30 2024-06-14 杭州英创医药科技有限公司 一类含有稠合三环结构的化合物
WO2022002118A1 (zh) * 2020-07-01 2022-01-06 四川海思科制药有限公司 一种并环杂环衍生物及其在医药上的应用
WO2023122662A1 (en) * 2021-12-22 2023-06-29 The Regents Of The University Of California Covalently binding inhibitors of g12s, g12d and/or g12e mutants of k-ras gtpase
CA3244694A1 (en) * 2022-02-23 2023-08-31 Assia Chemical Industries Ltd. SOLID FORMS OF GUSACITINIB
WO2023192989A2 (en) * 2022-04-01 2023-10-05 Azkarra Therapeutics, Inc. Phthalazinone compounds as parp7 inhibitors
WO2025024765A1 (en) 2023-07-27 2025-01-30 Libertas Bio, Inc. Solid state forms of gusacitinib
WO2025020171A1 (en) * 2023-07-27 2025-01-30 Libertas Bio, Inc. Crystalline forms of a jak/syk inhibitor

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE756508A (fr) * 1969-09-24 1971-03-01 Takeda Chemical Industries Ltd Derives de pyrimidopyridazine
CA1004223A (en) * 1972-05-12 1977-01-25 Theodor Denzel Amino derivatives of pyrido(2,3-d)pyridazine carboxylic acids and esters
JPS4948695U (enExample) 1972-07-29 1974-04-27
JPS50101387A (enExample) * 1974-01-16 1975-08-11
CA1052046A (en) 1974-01-21 1979-04-03 American Cyanamid Company Unsymmetrically substituted 1,4-dioxane-2,5-diones
US5369086A (en) 1993-04-28 1994-11-29 Zeneca Limited N-benzotriazoles
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
JPH0948695A (ja) 1995-08-02 1997-02-18 Toshiba Ceramics Co Ltd シリコン単結晶の製造方法
WO1999043671A1 (en) 1998-02-25 1999-09-02 Pharmacia & Upjohn Company Substituted aminomethyl isoxazoline derivatives useful as antimicrobials
KR100658489B1 (ko) 1998-11-10 2006-12-18 얀센 파마슈티카 엔.브이. Hiv 복제를 억제하는 피리미딘
CA2422054C (en) * 2000-09-22 2011-01-11 Akzo Nobel Nv Bicyclic heteroaromatic compounds
JP2004528349A (ja) 2001-04-30 2004-09-16 グラクソ グループ リミテッド 副腎皮質刺激ホルモン放出因子(crf)のアンタゴニストとしての縮合ピリミジン類
AU2003212634A1 (en) 2002-03-11 2003-09-22 Zetiq Technologies Ltd. Compounds useful in the treatment of cancer
MXPA05001096A (es) 2002-07-29 2005-11-23 Rigel Pharmaceuticals Inc Metodos para tratamiento o prevencion de enfermedades autoinmunes con compuestos de 2,4-diamino-pirimidina.
US7550590B2 (en) 2003-03-25 2009-06-23 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
AU2004265288A1 (en) 2003-07-30 2005-02-24 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
TW200538120A (en) 2004-02-20 2005-12-01 Kirin Brewery Compound having TGF-beta inhibitory activity and pharmaceutical composition containing same
RU2405778C2 (ru) 2004-09-30 2010-12-10 Тиботек Фармасьютикалз Лтд. 5-гетероциклилпиримидины, ингибирующие вич
US7795275B2 (en) 2004-12-24 2010-09-14 Uniquest Pty Limited Method of treatment or prophylaxis
JP2008534479A (ja) 2005-03-25 2008-08-28 テイボテク・フアーマシユーチカルズ・リミテツド Hcvの複素二環式阻害剤
WO2006105063A1 (en) 2005-03-25 2006-10-05 Scios Inc. Heterobicylic inhibitors of tgfbeta
DE602006007832D1 (de) 2005-04-29 2009-08-27 Janssen Pharmaceutica Nv Benzotriazolderivate als cannabinoidrezeptorantagonisten
EP1970373A1 (en) * 2005-12-02 2008-09-17 Mitsubishi Tanabe Pharma Corporation Alicyclic heterocyclic compound
US20070161670A1 (en) 2006-01-09 2007-07-12 Bristol-Myers Squibb Company Process for the preparation of substituted heterocycles
JP2009535393A (ja) 2006-05-01 2009-10-01 ファイザー・プロダクツ・インク 置換2−アミノ縮合複素環式化合物
GB0625196D0 (en) 2006-12-18 2007-01-24 7Tm Pharma As Modulators of cannabinoid receptor
CN103690542B (zh) * 2006-12-28 2015-11-18 Abbvie公司 聚(adp-核糖)聚合酶抑制剂
GEP20135925B (en) 2007-03-14 2013-10-10 Exelixis Patent Co Llc Inhibitors of hedgehog pathway
TW200942537A (en) 2008-02-01 2009-10-16 Irm Llc Compounds and compositions as kinase inhibitors
MX2011003447A (es) * 2008-09-30 2011-07-29 Astrazeneca Ab Inhibidores heterociclicos de jak quinasa.
AR073760A1 (es) 2008-10-03 2010-12-01 Astrazeneca Ab Derivados heterociclicos y metodos de uso de los mismos
AR073949A1 (es) 2008-10-21 2010-12-15 Metabolex Inc Agonistas del receptor aril-gpr120 y usos de los mismos
MX2012004846A (es) * 2009-10-29 2012-10-05 Genosco Inhibidores de cinasa.
TW201130852A (en) * 2009-12-23 2011-09-16 Abbott Lab Novel thienopyrrole compounds
WO2012058671A1 (en) 2010-10-31 2012-05-03 Endo Pharmaceuticals Inc. Substituted quinazoline and pyrido-pyrimidine derivatives
MX361458B (es) * 2011-08-23 2018-12-06 Asana Biosciences Llc Compuestos de pirimido-piridazinona y uso de los mismos.
WO2014022728A1 (en) 2012-08-02 2014-02-06 Endo Pharmaceuticals, Inc Substituted 5 - (quinazolin - 2 - yl) pyrimidin- 2 -amine derivatives useful as pi3k/mtor inhibitors for the treatment of cancer
AR106830A1 (es) * 2015-12-04 2018-02-21 Asana Biosciences Llc Usos de piridazinonas para tratar el cáncer
WO2018201131A1 (en) * 2017-04-28 2018-11-01 Asana Biosciences, Llc Formulations, methods, kits, and dosage forms for treating atopic dermatitis and for improved stability of an active pharmaceutical ingredient

Also Published As

Publication number Publication date
EP4327886A2 (en) 2024-02-28
MX2014002112A (es) 2014-09-25
JP5993010B2 (ja) 2016-09-14
CN108707151B (zh) 2022-06-03
WO2013028818A1 (en) 2013-02-28
DK3392252T3 (da) 2024-01-08
CN108707151A (zh) 2018-10-26
IL231082A0 (en) 2014-03-31
DK2748166T3 (en) 2018-10-29
EP2748166B1 (en) 2018-07-11
PL2748166T3 (pl) 2019-05-31
US20200190095A1 (en) 2020-06-18
CN103974955A (zh) 2014-08-06
US20140221315A1 (en) 2014-08-07
BR112014003981A2 (pt) 2017-03-07
US9382277B2 (en) 2016-07-05
EP3404029A2 (en) 2018-11-21
CN103974955B (zh) 2018-06-19
US20190092779A1 (en) 2019-03-28
US20130053346A1 (en) 2013-02-28
US10183944B2 (en) 2019-01-22
FI3392252T3 (fi) 2024-01-08
WO2013028818A8 (en) 2013-09-19
JP2014524475A (ja) 2014-09-22
US20160257691A1 (en) 2016-09-08
ES2969977T3 (es) 2024-05-23
MX361458B (es) 2018-12-06
EP2748166A1 (en) 2014-07-02
EP4327886A3 (en) 2024-05-22
EP3392252A1 (en) 2018-10-24
US8729079B2 (en) 2014-05-20
EP3404029A3 (en) 2018-12-12
EP3392252B1 (en) 2023-10-04
HUE065564T2 (hu) 2024-06-28
US10647720B2 (en) 2020-05-12
CA2846187A1 (en) 2013-02-28
IL231082A (en) 2016-09-29

Similar Documents

Publication Publication Date Title
ES2690971T3 (es) Compuestos pirimido-piridazinona y uso de los mismos
ES2637167T3 (es) Compuestos de tetrahidro-pirido-piridina y tetrahidro-pirido-pirimidina y su uso como moduladores de los receptores de C5a
AR102948A1 (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo como inhibidores del receptor p2x3
PH12015501934A1 (en) New octahydro - pyrrolo [3,4-c] - pyrrole derivatives and analogs thereof as autotaxin inhibitors
CR20150491A (es) 3-pirimidin-4-il oxazolidin -2- onas como inhibidores de idh mutante
CO6321230A2 (es) Compuesto espiro, una sal aceptable para uso farmaceutico y un solvato del mismo y composicion farmaceutica que lo contenga
TR201901566T4 (tr) Bir hareketli mobilya parçasının hareket ettirilmesi için tahrik tertibatı.
IN2014MN00228A (enExample)
AR097431A1 (es) Compuestos de carboxamida de furo y tienopiridina útiles como inhibidores de quinasas pim
UY33489A (es) Derivados de indolizina, su procediemiento de preparacion y su aplicacion en terapeutica
CR20160098A (es) Polimorfo de los inhibidores de la syk
EA201691031A1 (ru) Синтез макроциклического трипептида, ингибирующего hcv ns3
MX2016014238A (es) Composicion limpiadora.
ES2653265T3 (es) Morfinanos sustituidos y el uso de éstos
UA112993C2 (uk) Піперазинзаміщені похідні бензотіофену як антипсихотичні агенти
UA112428C2 (uk) Пестицидні композиції і пов'язані з ними способи
Pejović et al. Discovery of anxiolytic 2-ferrocenyl-1, 3-thiazolidin-4-ones exerting GABAA receptor interaction via the benzodiazepine-binding site
MA38982A1 (fr) Nouvel octahydro-cyclobuta [1,2-c; 3,4-c'] dipyrrol-2-yl
AR090572A1 (es) Derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos
MX2016005233A (es) Sonda de formacion de imagenes para tau.
AR088596A1 (es) Compuestos de bencilamina sustituidos
MX2017003782A (es) Derivado de isoxazol como inhibidor de isocitrato deshidrogenasa 1 mutante.
AR113811A1 (es) Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos
AR100940A1 (es) Derivados de 1,2,4-triazoles plaguicidas, y sus intermediarios, composiciones y sus procesos relacionados
AR088510A1 (es) Moduladores de trpv3